Clinical, Biochemical and Radiological Profile of MASLD in a Tertiary Care Hospital: A Cross-Sectional Study

Abstract

Background

Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is a major contributor to chronic liver disease and is strongly linked with metabolic abnormalities such as obesity, diabetes, and dyslipidemia. Non-invasive tools like Fibroscan are increasingly used for disease assessment.

Objective

To ascertain the clinical, biochemical, and radiological profile of patients with MASLD and their association with metabolic risk factors.

Methods

A hospital-based cross-sectional study was conducted among 63 MASLD patients. Clinical parameters, biochemical investigations, and Fibroscan findings (CAP and liver stiffness) were recorded. Statistical analysis included Chi-square test and Spearman correlation, with significance set at p < 0.05.

Results

The mean age was 44.75 ± 11.64 years, with 63.5% males. A high prevalence of obesity (82.5%) and dysglycemia (81%) was observed. Severe steatosis (S3) was present in 54% of patients. Most patients had early fibrosis (F0–F1), though ~19% had advanced fibrosis. BMI showed a significant association with CAP score (p = 0.002), while AST was significantly associated with fibrosis severity (p = 0.007).

Conclusion

MASLD is strongly associated with metabolic dysfunction, particularly obesity and dysglycemia. Anthropometric and biochemical parameters, along with Fibroscan, play a key role in disease assessment and risk stratification.